Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Trial of Telmisartan 80 mg/HCTZ 12.5 mg and Telmisartan 40 mg/HCTZ 12.5 mg in Patients With Hypertension
This study has been completed.
Study NCT00326768 Information provided by Boehringer Ingelheim Pharmaceuticals
First Received: May 16, 2006 Last Updated: November 25, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Hypertension
More general conditions related to this trial
Cardiovascular Diseases
Vascular Diseases
Interventions listed in this trial
Telmisartan 40 mg/HCTZ 12.5 mg
Telmisartan 40 mg
Telmisartan 80 mg/HCTZ 12.5 mg
Additional drug interventions recognized in this trial
Benzoates
Hydrochlorothiazide
Telmisartan
More general drug interventions related to this trial
Angiotensin II Type 1 Receptor Blockers
Angiotensin-Converting Enzyme Inhibitors
Anti-Infective Agents
Antifungal Agents
Antihypertensive Agents
Cardiovascular Agents
Diuretics
Enzyme Inhibitors
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Natriuretic Agents
Pharmacologic Actions
Physiological Effects of Drugs
Protease Inhibitors
Sodium Chloride Symporter Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Boehringer Ingelheim Pharmaceuticals
Back to top of Main Content
